WENA Profile
Anew Medical, Inc. leads the charge in developing revolutionary therapies targeting age-related cognitive decline, neurodegenerative disorders, and cancer. Our pioneering approach integrates state-of-the-art cell and gene therapies aimed at disrupting the progression of devastating conditions such as Alzheimer's disease and various cancers. Through innovative scientific methodologies, we are dedicated to delivering treatments that offer profound and lasting therapeutic benefits.
At the core of our innovation strategy lie two pivotal platform technologies exclusively licensed by Anew Medical, Inc. These encompass biosimilar biologics focusing on cancer treatment, particularly biosimilars of Roche/Genentech's bevacizumab (Avastin) and rituximab (Mabthera and Rituxan), renowned for their efficacy in the market. Additionally, we have acquired cutting-edge gene therapy technology utilizing the a-Klotho gene. This groundbreaking approach aims to harness a novel truncated protein (s+KL) that mimics the functions of the full-length soluble a-Klotho protein (s-KL), offering potential advancements in anti-aging treatments and combating neurodegenerative diseases.
Founded with a commitment to advancing medical science, Anew Medical, Inc. collaborates closely with corporate partners to bring blockbuster biologic drugs to market. Our focus extends to commercializing therapies that demonstrate efficacy and similarity to established reference antibodies. By spearheading these innovative therapies, we aspire to redefine treatment standards and significantly enhance patient outcomes worldwide.
|
